Lung Adenocarcinoma Size Decrease after SARS-CoV-2 Vaccination during Long-Term Pembrolizumab Treatment: A Case Report

A man in his late 40s was diagnosed with clinical stage 4B lung adenocarcinoma with a PD-L1 tumor proportion score of 100% and high tumor mutational burden. A partial response was achieved after administration of pembrolizumab. The patient received two doses of a SARS-CoV-2 vaccine (BNT162b2) after...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujii, Koki, Fukuda, Kensuke, Kawakami, Masanori, Mitani, Akihisa, Tanaka, Goh, Kage, Hidenori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601772/
https://www.ncbi.nlm.nih.gov/pubmed/37900823
http://dx.doi.org/10.1159/000533705
_version_ 1785126261326086144
author Fujii, Koki
Fukuda, Kensuke
Kawakami, Masanori
Mitani, Akihisa
Tanaka, Goh
Kage, Hidenori
author_facet Fujii, Koki
Fukuda, Kensuke
Kawakami, Masanori
Mitani, Akihisa
Tanaka, Goh
Kage, Hidenori
author_sort Fujii, Koki
collection PubMed
description A man in his late 40s was diagnosed with clinical stage 4B lung adenocarcinoma with a PD-L1 tumor proportion score of 100% and high tumor mutational burden. A partial response was achieved after administration of pembrolizumab. The patient received two doses of a SARS-CoV-2 vaccine (BNT162b2) after 59 courses, and a chest computed tomography revealed consolidation in the peri-tumoral area, which subsequently disappeared, and the tumor continued to shrink in the next 4 months. This case provides indirect evidence for the persistence of cancer immunity during long-term treatment with immune checkpoint inhibitors and the potential for further activation.
format Online
Article
Text
id pubmed-10601772
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-106017722023-10-27 Lung Adenocarcinoma Size Decrease after SARS-CoV-2 Vaccination during Long-Term Pembrolizumab Treatment: A Case Report Fujii, Koki Fukuda, Kensuke Kawakami, Masanori Mitani, Akihisa Tanaka, Goh Kage, Hidenori Case Rep Oncol Case Report A man in his late 40s was diagnosed with clinical stage 4B lung adenocarcinoma with a PD-L1 tumor proportion score of 100% and high tumor mutational burden. A partial response was achieved after administration of pembrolizumab. The patient received two doses of a SARS-CoV-2 vaccine (BNT162b2) after 59 courses, and a chest computed tomography revealed consolidation in the peri-tumoral area, which subsequently disappeared, and the tumor continued to shrink in the next 4 months. This case provides indirect evidence for the persistence of cancer immunity during long-term treatment with immune checkpoint inhibitors and the potential for further activation. S. Karger AG 2023-09-13 /pmc/articles/PMC10601772/ /pubmed/37900823 http://dx.doi.org/10.1159/000533705 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Fujii, Koki
Fukuda, Kensuke
Kawakami, Masanori
Mitani, Akihisa
Tanaka, Goh
Kage, Hidenori
Lung Adenocarcinoma Size Decrease after SARS-CoV-2 Vaccination during Long-Term Pembrolizumab Treatment: A Case Report
title Lung Adenocarcinoma Size Decrease after SARS-CoV-2 Vaccination during Long-Term Pembrolizumab Treatment: A Case Report
title_full Lung Adenocarcinoma Size Decrease after SARS-CoV-2 Vaccination during Long-Term Pembrolizumab Treatment: A Case Report
title_fullStr Lung Adenocarcinoma Size Decrease after SARS-CoV-2 Vaccination during Long-Term Pembrolizumab Treatment: A Case Report
title_full_unstemmed Lung Adenocarcinoma Size Decrease after SARS-CoV-2 Vaccination during Long-Term Pembrolizumab Treatment: A Case Report
title_short Lung Adenocarcinoma Size Decrease after SARS-CoV-2 Vaccination during Long-Term Pembrolizumab Treatment: A Case Report
title_sort lung adenocarcinoma size decrease after sars-cov-2 vaccination during long-term pembrolizumab treatment: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601772/
https://www.ncbi.nlm.nih.gov/pubmed/37900823
http://dx.doi.org/10.1159/000533705
work_keys_str_mv AT fujiikoki lungadenocarcinomasizedecreaseaftersarscov2vaccinationduringlongtermpembrolizumabtreatmentacasereport
AT fukudakensuke lungadenocarcinomasizedecreaseaftersarscov2vaccinationduringlongtermpembrolizumabtreatmentacasereport
AT kawakamimasanori lungadenocarcinomasizedecreaseaftersarscov2vaccinationduringlongtermpembrolizumabtreatmentacasereport
AT mitaniakihisa lungadenocarcinomasizedecreaseaftersarscov2vaccinationduringlongtermpembrolizumabtreatmentacasereport
AT tanakagoh lungadenocarcinomasizedecreaseaftersarscov2vaccinationduringlongtermpembrolizumabtreatmentacasereport
AT kagehidenori lungadenocarcinomasizedecreaseaftersarscov2vaccinationduringlongtermpembrolizumabtreatmentacasereport

Ejemplares similares